211 related articles for article (PubMed ID: 18397343)
1. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
2. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
De Vita S; Mulligan C; McElwaine S; Dagna-Bricarelli F; Spinelli M; Basso G; Nizetic D; Groet J
Br J Haematol; 2007 May; 137(4):337-41. PubMed ID: 17456055
[TBL] [Abstract][Full Text] [Related]
3. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
4. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
[TBL] [Abstract][Full Text] [Related]
6. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
7. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
8. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
9. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
10. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations in human acute megakaryoblastic leukemia.
Malinge S; Ragu C; Della-Valle V; Pisani D; Constantinescu SN; Perez C; Villeval JL; Reinhardt D; Landman-Parker J; Michaux L; Dastugue N; Baruchel A; Vainchenker W; Bourquin JP; Penard-Lacronique V; Bernard OA
Blood; 2008 Nov; 112(10):4220-6. PubMed ID: 18755984
[TBL] [Abstract][Full Text] [Related]
13. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
14. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Riera L; Lasorsa E; Bonello L; Sismondi F; Tondat F; Di Bello C; Di Celle PF; Chiarle R; Godio L; Pich A; Facchetti F; Ponzoni M; Marmont F; Zanon C; Bardelli A; Inghirami G
Leuk Lymphoma; 2011 Sep; 52(9):1742-50. PubMed ID: 21599579
[TBL] [Abstract][Full Text] [Related]
15. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
16. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
Kiyoi H; Yamaji S; Kojima S; Naoe T
Leukemia; 2007 Mar; 21(3):574-6. PubMed ID: 17252020
[No Abstract] [Full Text] [Related]
17. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; Loriaux M; Goss VL; Lee KA; Eide CA; Wong MJ; Stoffregen EP; McGreevey L; Nardone J; Moore SA; Crispino J; Boggon TJ; Heinrich MC; Deininger MW; Polakiewicz RD; Gilliland DG; Druker BJ
Cancer Cell; 2006 Jul; 10(1):65-75. PubMed ID: 16843266
[TBL] [Abstract][Full Text] [Related]
18. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
19. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
20. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
